Clearmind Medicine Secures CAD$1.6 Million in Private Placement
February 8, 2022
Ryan Allway February 8th, 2022 Psychedelics, Top News Clearmind and Medigus, the investor, intend to form a joint venture in the field of food industry, based on Clearmind’s unique psychedelics IP TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the “Company“), a... Read more
Rapid Dose Therapeutics Strengthens Leadership Team with Addition of Rodney Butt & Appoints New Advisory Board Member
Biotechnology December 15, 2021
Ryan Allway December 15th, 2021 Additions to support immediate commercialization efforts for the Company’s COVID-19 vaccine candidate BURLINGTON, Ontario, December 15, 2021–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is pleased to announce a significant addition to... Read more
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
December 15, 2021
Ryan Allway December 15th, 2021 Psychedelics – Expands intellectual property portfolio and strengthens position as leading innovator in developing putative psychedelic compounds – TORONTO–(BUSINESS WIRE)– Cybin Inc. ( NEO:CYBN) ( NYSE American:CYBN) (“ Cybin” or the “ Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM” today announced that it has been awarded a... Read more
